Micrognathia
Methodology & AI Transparency ⓘ
Micrognathia Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Micrognathia—coded clinically as M26.09 across Arthritis & Joints guidelines—combines weight-bearing joint radiography [Micrognathia M26.09] with structured follow-up of Weight-Bearing Joint Radiograph [Micrognathia M26.09] (Preserved joint-space width (M26.09)).
- 2 Real-world patient consensus: Diagnostic registry M26.09: Micrognathia is managed within Arthritis & Joints.
- 3 Typical cash cost range: Primary evaluation for Micrognathia incorporates weight-bearing joint radiography [Micrognathia M26.09] and symptom diary review.
- 4 Top reported side effects / signs: Key Arthritis & Joints biomarkers for Micrognathia (M26.09): hs-CRP & Erythrocyte in Micrognathia (M26.09: Sedimentation Rate) & Weight-Bearing Joint Radiograph [Micrognathia M26.09] (Preserved joint-space width (M26.09)).
Ask our AI Specialists anything about Micrognathia
What Is Micrognathia?
Micrognathia—coded clinically as M26.09 across Arthritis & Joints guidelines—combines weight-bearing joint radiography [Micrognathia M26.09] with structured follow-up of Weight-Bearing Joint Radiograph [Micrognathia M26.09] (Preserved joint-space width (M26.09)).
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Micrognathia (M26.09, Arthritis & Joints) reflects monosodium urate or in Micrognathia (M26.09: calcium pyrophosphate crystal). longitudinal control is benchmarked via hs-CRP & Erythrocyte in Micrognathia (M26.09: Sedimentation Rate).
Common Symptoms & Clinical Signs
- • Presentation of Micrognathia (M26.09): brief morning joint in Micrognathia (M26.09: stiffness)
- • Secondary Micrognathia clinical sign: sudden, intensely painful, in Micrognathia (M26.09: red swollen big-toe)
- • Symptom flares in Micrognathia correlating with hs-CRP & Erythrocyte in Micrognathia (M26.09: Sedimentation Rate) deviation outside hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M26.09)
- • Functional arthritis & joints impact requiring weight-bearing joint radiography [Micrognathia M26.09] evaluation (M26.09)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Micrognathia Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M26.09 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Micrognathia (M26.09: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M26.09) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Micrognathia M26.09] | Preserved joint-space width (M26.09) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Uric Acid in Micrognathia (M26.09: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M26.09) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Micrognathia
Treatment selection for Micrognathia depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Micrognathia)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Olokizumab, a monoclonal antibody against interleukin 6, in combination with: What a 428-Participant Study Found Treatment with OKZ was associated with significant improvement in signs, symptoms and physical function of autoimmune joint pain (autoimmune joint pain (rheumatoid arthritis)) without discernible differences between the two... Annals of the rheumatic diseases • 2022-04-15 • Phase III Randomized Trial | N = 428 | 93/100 | PMID 34344706 ↗ |
| Can This Approach Help? Inside the Latest Research on Rituximab plus leflunomide in autoimmune joint pain (rheumatoid arthritis): a The primary endpoint was not reached, but rituximab + LEF demonstrated clinical benefits vs LEF in secondary endpoints. Rheumatology (Oxford, England) • 2021-11-03 • Phase III Randomized Trial | N = 93 | 88/100 | PMID 33738492 ↗ |
| Can This Approach Help? Inside the Latest Research on Baricitinib Dose Reduction in Patients With autoimmune joint pain (rheumatoid In a randomized, blinded, phase III LTE study, maintenance of disease control following induction of sustained LDA/REM with baricitinib 4 mg was greater with continued 4 mg than after tapering to 2 mg. The Journal of rheumatology • 2025-04-01 • Phase III Randomized Trial | N = 112 | 82/100 | PMID 39814441 ↗ |
Micrognathia Patient Community & “People Like Me” Threads
Filter Micrognathia community threads and patient logs by age, biological sex, dosage, and treatment duration.